Invesaro

Stocks Comparison

Charles River Laboratories International vs OmniAb: revenue, profit, margins and growth compared

Charles River Laboratories International brought in $4B of revenue in fiscal 2025, OmniAb $18.7M in fiscal 2025. Revenue changed by -0.9% at Charles River Laboratories International and -29.3% at OmniAb on the year before, so Charles River Laboratories International grew faster. Charles River Laboratories International kept -3.6% of its revenue as net profit, OmniAb -347.0%. Free cash flow was $518.5M at Charles River Laboratories International and -$37M at OmniAb.

Side by side, latest fiscal year

CRLOABI
Fiscal year endedFY2025 (December 27, 2025)FY2025 (December 31, 2025)
Revenue$4B$18.7M
Revenue growth-0.9%-29.3%
Net income-$144.3M-$64.8M
Net margin-3.6%-347.0%
Free cash flow$518.5M-$37M
Free cash flow margin12.9%-198.3%
Earnings per share (diluted)-$2.91-$0.57
Cash$213.8M$25.5M
Debt$166Kn/a
Price to earningsn/an/a
Market value$14B$670.2M
Dividend yieldn/an/a
Rank by revenue in sector#72 of 523 · Health care#413 of 523 · Health care

Over the years

Revenue
CRL FY2018: $2.3BCRL FY2019: $2.6BCRL FY2020: $2.9BCRL FY2021: $3.5BCRL FY2022: $4BCRL FY2023: $4.1BCRL FY2024: $4BCRL FY2025: $4BOABI FY2021: $34.7MOABI FY2022: $59.1MOABI FY2023: $34.2MOABI FY2024: $26.4MOABI FY2025: $18.7MFY18FY19FY20FY21FY22FY23FY24FY25
CRL $4BOABI $18.7M
Net income
CRL FY2018: $226.4MCRL FY2019: $252MCRL FY2020: $364.3MCRL FY2021: $391MCRL FY2022: $486.2MCRL FY2023: $474.6MCRL FY2024: $22.2MCRL FY2025: -$144.3MOABI FY2021: -$27MOABI FY2022: -$22.3MOABI FY2023: -$50.6MOABI FY2024: -$62MOABI FY2025: -$64.8MFY18FY19FY20FY21FY22FY23FY24FY25
CRL -$144.3MOABI -$64.8M
Net margin
CRL FY2018: 10.0%CRL FY2019: 9.6%CRL FY2020: 12.5%CRL FY2021: 11.0%CRL FY2022: 12.2%CRL FY2023: 11.5%CRL FY2024: 0.5%CRL FY2025: -3.6%OABI FY2021: -77.8%OABI FY2022: -37.8%OABI FY2023: -148.2%OABI FY2024: -235.1%OABI FY2025: -347.0%FY18FY19FY20FY21FY22FY23FY24FY25
CRL -3.6%OABI -347.0%
Revenue growth
CRL FY2019: +15.7%CRL FY2020: +11.5%CRL FY2021: +21.1%CRL FY2022: +12.3%CRL FY2023: +3.9%CRL FY2024: -1.9%CRL FY2025: -0.9%OABI FY2022: +70.0%OABI FY2023: -42.2%OABI FY2024: -22.8%OABI FY2025: -29.3%FY19FY20FY21FY22FY23FY24FY25
CRL -0.9%OABI -29.3%
Free cash flow
CRL FY2018: $301.1MCRL FY2019: $340.4MCRL FY2020: $380MCRL FY2021: $532MCRL FY2022: $294.9MCRL FY2023: $365.4MCRL FY2024: $501.6MCRL FY2025: $518.5MOABI FY2021: -$9.7MOABI FY2022: -$20.8MOABI FY2023: $703KOABI FY2024: -$41.5MOABI FY2025: -$37MFY18FY19FY20FY21FY22FY23FY24FY25
CRL $518.5MOABI -$37M

Fiscal years as each company reports them; the two may end in different months.

Questions about Charles River Laboratories International and OmniAb

Which is bigger by revenue, Charles River Laboratories International or OmniAb?

Charles River Laboratories International is bigger by revenue: $4B in fiscal 2025, against $18.7M for OmniAb in fiscal 2025.

Which keeps more of its revenue as profit, Charles River Laboratories International or OmniAb?

Charles River Laboratories International had a net margin of -3.6% in fiscal 2025; OmniAb had -347.0% in fiscal 2025.

Which grew revenue faster, Charles River Laboratories International or OmniAb?

In their latest fiscal years revenue changed by -0.9% at Charles River Laboratories International and -29.3% at OmniAb.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies